Key Highlights
- Launch of Patholytix Foresight, a collaborative AI tool by Charles River and Deciphex, aimed at enhancing toxicologic pathology.
- Combines AI with digital pathology solutions to accelerate drug development and safety assessments.
- Features organ-based lesion classifiers and integrates with Whole Slide Images for improved decision-making in pathology.
Source: Business Wire
Notable Quotes
- “AI-powered solutions are accelerating the pace and efficiency of drug development, and the launch of Patholytix Foresight marks a significant milestone in our collaborative efforts to enhance the digital transformation of toxicological pathology.” – Professor Julie Frearson, PhD, Corporate Senior Vice President, Chief Scientific Officer at Charles River
- “In collaboration with Charles River Laboratories, we look forward to bringing Patholytix Foresight to the forefront of digital pathology, empowering pathologists worldwide with cutting-edge AI technology for more efficient and accurate toxicological assessments.” – Pierre Moulin, MD, PhD, MBA, Chief Scientific Officer at Deciphex
SoHC's Take
The introduction of Patholytix Foresight represents a pivotal advance in the field of toxicologic pathology. By leveraging artificial intelligence, Charles River and Deciphex are setting new standards in the precision and efficiency of pathology assessments. This tool is not just a technological upgrade; it is a paradigm shift towards more reliable and expedient drug safety evaluations, reflecting a broader trend towards digital transformation in biotechnology and pharmaceutical industries. The strategic collaboration between these two industry leaders underscores the increasing importance of integrating digital technologies to enhance traditional methodologies and improve outcomes in healthcare research and diagnostics.
